Brief introduction of 763111-47-3

The synthetic route of 763111-47-3 has been constantly updated, and we look forward to future research findings.

763111-47-3, 4-(4-Fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one is a phthalazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A QMA cartridge containing cyclotron -produced [18F] fluoride ion was euted with a solution containing 9 mg Kryptofix [2.2,2] (4,7.13, 16,21,24- hexaoxa- l,10-diaza bicycloi8.8.8]hexacosane), 0.08 m L 0.15 M K2C03 and 1.92 m L MeCN into a 5 m L reaction vial. Water was removed azeotropically at 120 C. 500 mug of ethyl 4-nitrobenzoate dissolved in 100 mu of DMSO was then added to the reaction vial and heated to 150 C for 15 minutes. The reaction via l was then allowed to cool as 50 mu of 1M NaOH was added. The reaction mixture was stirred for 1 min and 50 mu of 1M HCI was added to quench. Then, 2 mg of 4-(4-fiuoro-3-(piperazine-l-carbonyl)benzyi)phthaiazin- l(2H)-one dissolved in 100 mu of DMSO was added , followed by 10 mg of HBT U dissolved in 100 mu of DMSO and 20 mu. of Et3N. The reaction mixture was stirred for 1 minute. 400 mu MeCN followed by 700 mu H20 was then added and the solution was injected onto a C6-Pheny analytical HPLC column and eluted under isocratic conditions (Method B: 30% acetonitrile in water for 35min). Compound C- 2f eluted at (tR = 25.5 min), which was well resolved from the nitro analogue (4-(4-fluoro-3-(4-(4- nitrobenzoyl)piperazine-l-carbonyl)benzyl)phthalazin-l(2H)-one; tR = 30.1 min). For intravenous administration, the product-containing fraction was passed through a CIS light-SepPak cartridge preconditioned with EtOH (10 m L) and water (10 mL). The cartridge was washed with water (3 m L) and C-2f was eluted using EtOH (400 mu). The solution was then diluted with 0.9% saline to 10% EtOH. The radiochemical purity of the final formulation was confirmed using analytical HPLC.

The synthetic route of 763111-47-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MEMORIAL SLOAN KETTERING CANCER CENTER; REINER, Thomas; LEWIS, Jason S.; WEBER, Wolfgang; RODRIGUEZ, Beatriz Salinas; CARNEY, Brandon; CARLUCCI, Giuseppe; (89 pag.)WO2016/33293; (2016); A1;,
Phthalazine – Wikipedia
Phthalazine | C8H6N2 – PubChem